✅ Revenue growth is accelerating (27% YoY), and ARR is expanding.
✅ US market entry (FDA approval) is the major catalyst—$100M revenue potential.
✅ Infant App has strong global potential in the direct-to-consumer market.
✅ Pipeline expansion (telehealth, disabilities app) ensures long-term growth.
⚠️ Short-term losses continue due to investment in growth.
⚠️ Execution on US market entry and Infant App commercialization is key.
Add to My Watchlist
What is My Watchlist?
